612 related articles for article (PubMed ID: 19875543)
1. Defining and characterizing the progression of type 2 diabetes.
Fonseca VA
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S151-6. PubMed ID: 19875543
[No Abstract] [Full Text] [Related]
2. Managing postprandial glucose levels in patients with diabetes.
Tenzer-Iglesias P; Brunton S
J Fam Pract; 2008 Jan; 57(1 Suppl Managing):S17-24. PubMed ID: 18662529
[No Abstract] [Full Text] [Related]
3. Postprandial hyperglycaemia--its importance and implications.
Lüddeke HJ
Int J Clin Pract Suppl; 1999 Jul; 104():3-7; discussion 18-20. PubMed ID: 12669731
[No Abstract] [Full Text] [Related]
4. Determining pancreatic β-cell compensation for changing insulin sensitivity using an oral glucose tolerance test.
Solomon TP; Malin SK; Karstoft K; Knudsen SH; Haus JM; Laye MJ; Pedersen M; Pedersen BK; Kirwan JP
Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E822-9. PubMed ID: 25184989
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.
Hazama Y; Matsuhisa M; Ohtoshi K; Gorogawa S; Kato K; Kawamori D; Yoshiuchi K; Nakamura Y; Shiraiwa T; Kaneto H; Yamasaki Y; Hori M
Diabetes Res Clin Pract; 2006 Mar; 71(3):251-5. PubMed ID: 16214255
[TBL] [Abstract][Full Text] [Related]
6. Genetic and environmental interaction in Japanese type 2 diabetics.
Matsuoka K
Diabetes Res Clin Pract; 2000 Oct; 50 Suppl 2():S17-22. PubMed ID: 11024579
[TBL] [Abstract][Full Text] [Related]
7. Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin.
Takahara M; Shiraiwa T; Matsuoka TA; Katakami N; Shimomura I
Endocr J; 2015; 62(1):77-86. PubMed ID: 25328035
[TBL] [Abstract][Full Text] [Related]
8. Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity.
Matthews DR; Zinman B; Tong C; Meininger G; Polidori D
Diabet Med; 2016 Dec; 33(12):1744-1747. PubMed ID: 26600115
[No Abstract] [Full Text] [Related]
9. Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes.
Koga M; Murai J; Saito H; Kasayama S
Diabetes Care; 2010 Feb; 33(2):270-2. PubMed ID: 19846794
[TBL] [Abstract][Full Text] [Related]
10. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.
Defronzo RA
Diabetes; 2009 Apr; 58(4):773-95. PubMed ID: 19336687
[No Abstract] [Full Text] [Related]
11. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
[TBL] [Abstract][Full Text] [Related]
12. Type 2 diabetes mellitus in children and adolescents.
Nesmith JD
Pediatr Rev; 2001 May; 22(5):147-52. PubMed ID: 11331736
[No Abstract] [Full Text] [Related]
13. [Medical treatment of type 2 diabetes. Recommendations for good practice].
Diabetes Metab; 2007 Jan; 33(1 Pt 2):1S26-105. PubMed ID: 17499188
[No Abstract] [Full Text] [Related]
14. Comparison of fasting capillary glucose variability between insulin glargine and NPH.
Mu P; Lu H; Zhang G; Chen Y; Fu J; Wang M; Shu J; Zeng L
Diabetes Res Clin Pract; 2011 Jan; 91(1):e4-7. PubMed ID: 20970870
[TBL] [Abstract][Full Text] [Related]
15. Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients.
Shiraiwa T; Kaneto H; Miyatsuka T; Kato K; Yamamoto K; Kawashima A; Kanda T; Suzuki M; Imano E; Matsuhisa M; Hori M; Yamasaki Y
Diabetes Care; 2005 Nov; 28(11):2806-7. PubMed ID: 16249562
[No Abstract] [Full Text] [Related]
16. Early insulin treatment in type 2 diabetes: what are the pros?
Meneghini LF
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S266-9. PubMed ID: 19875562
[No Abstract] [Full Text] [Related]
17. [And what about diabetes?].
Cerasi E
Bull Acad Natl Med; 2007; 191(4-5):941-3; discussion 943. PubMed ID: 18225448
[TBL] [Abstract][Full Text] [Related]
18. The capability of glucose toxicity on severe type 2 diabetes.
Hsieh CH; Hung YJ; He CT; Lee CH; Hung SC; Wang YK; Kuo SW; Pei D
Endocr Res; 2005; 31(2):149-58. PubMed ID: 16353673
[TBL] [Abstract][Full Text] [Related]
19. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
Massi-Benedetti M; Orsini-Federici M
Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
[TBL] [Abstract][Full Text] [Related]
20. The Dual Amylin- and Calcitonin-Receptor Agonist KBP-042 Works as Adjunct to Metformin on Fasting Hyperglycemia and HbA1c in a Rat Model of Type 2 Diabetes.
Hjuler ST; Gydesen S; Andreassen KV; Karsdal MA; Henriksen K
J Pharmacol Exp Ther; 2017 Jul; 362(1):24-30. PubMed ID: 28438778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
